Table 2.
Panel of activators used to develop the whole blood assays.
| Target | Activator | Final concentration | Source |
|---|---|---|---|
| T cell polyclonal activation | PMA | 50 ng/mL | Sigma Aldrich |
| Ionomycin | 1 µg/mL | ||
| TLR1/2 | LTA (B Subtilis) | 100 µg/mL | Invivogen |
| TLR2 | Zymosan | 100 µg/mL | Molecular Probe |
| TLR2/6 | PGN (S. Aureus) | 100 µg/mL | Sigma Aldrich |
| TLR3 and RLR | Poly(I:C) HMW | 100 µg/mL | Invivogen |
| TLR4 | Ultrapure LPS (E Coli 0111:B4 strain) | 1 µg/mL | |
| TLR7/8 | Imiquimod (R837) | 100 µg/mL | |
| Resiquimod (R848) | 10 µg/mL | ||
| CL075 | 10 µg/mL | ||
| TLR9 | CpG-A (ODN 2336) | 50 µg/mL | |
| CpG-B (ODN 2006) | 50 µg/mL | ||
| TLR7 and Helicases | Inactivated Influenza M1 virus | 1000 HAU/mL | Sanofi-Pasteur |
| Type-I IFN | IFNα-2b | 1000 IU/mL | Roferon® |